logo

Emergent Biosolutions Inc (EBS)



Trade EBS now with
  Date
  Headline
11/20/2017 7:03:25 AM Emergent BioSolutions Gets FDA Approval To Manufacture ACAM2000 At Canton, Massachusetts Facility
10/4/2017 7:04:30 AM Emergent BioSolutions Gets Contract Valued At Up To About $25 Mln By U.S. Department Of State
10/3/2017 7:01:34 AM Emergent BioSolutions Completes Acquisition Of Raxibacumab From GSK
9/25/2017 7:06:56 AM Emergent To Supply DoD With Chemical Threat Countermeasure RSDL Under 5-yr Follow-On Contract Worth Up To $171 Mln
9/18/2017 8:07:37 AM Emergent BioSolutions Awarded $63 Mln BARDA Contract To Develop Treatment For Cyanide Exposure
7/14/2017 7:03:39 AM Emergent BioSolutions To Acquire ACAM2000 Business Of Sanofi In All-cash Transaction With Total Value Of Up To $125 Mln
3/31/2017 7:08:14 AM Emergent BioSolutions Signs $53 Mln Modification To BARDA Contract For The Manufacture Of Botulism Antitoxin
3/17/2017 7:03:33 AM Emergent BioSolutions Bags $100 Mln BARDA Contract For BioThrax Deliveries To Strategic National Stockpile
2/13/2017 7:05:48 AM Emergent BioSolutions Gets BARDA Task Order Valued At Up To $30.5 Mln To Develop Viral Hemorrhagic Fever Therapeutics
2/1/2017 7:15:26 AM Emergent BioSolutions Begins NIAID-Funded Phase 1b Clinical Study To Evaluate Broad-Spectrum Antiviral UV-4B For Dengue
1/27/2017 7:02:09 AM Emergent Gets German Federal Ministry Of Health Approval Of Building 55 For Large-Scale Manufacturing Of BioThrax
1/9/2017 7:09:28 AM Emergent BioSolutions Expects FY16 Revenues Of $500 Mln-$505 Mln, Net Income Of $44 Mln-$48 Mln, On Combined Basis
12/12/2016 7:06:47 AM Emergent BioSolutions Gets Health Canada Approval For Botulism Antitoxin
9/30/2016 9:32:25 AM Emergent Provides Update On The Status Of Its 2011 BioThrax Procurement Contract